Basel, Switzerland, March 01, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea's Management Committee as Chief Corporate Development Officer effective March 01, 2018. He will continue to be responsible for strategic planning, business development & licensing, investor relations and public relations.
Mr. Kaul has served as Basilea's Head of Corporate Development and as a member of Basilea's Extended Management Committee since March 2016. Before joining Basilea, he held various positions at Polyphor Ltd., including CFO and Head Corporate Development. Prior to this, he served as Basilea's Head Business Development, Licensing & Investor Relations and Head Public Relations & Corporate Communications. In addition, he was a senior financial analyst at Neue Zürcher Bank covering Swiss pharmaceutical and biotech stocks and held various positions in general management and sales & marketing at bioinformatics company Genedata AG. Mr. Kaul holds Master degrees both in biochemistry and economics from the University of Basel, and received an Executive MBA from HSG St. Gallen.
Ronald Scott, Chief Executive Officer, commented: "I am pleased to further strengthen our Management Committee by the addition of Adesh Kaul as Chief Corporate Development Officer. He has been leading our partnering activities, which has resulted in us successfully establishing development and commercialization partnerships for our hospital anti-infectives portfolio with leading pharmaceutical companies around the world. Under his leadership, our commercialized drugs are now partnered in over 100 countries. Adesh's expertise is particularly valuable for managing Basilea's strategic planning and business development activities as we continue to focus on strengthening our R&D portfolio."